Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Inventiva S.A. has garnered a consensus rating of "Moderate Buy" from six brokerages, with five analysts giving a buy rating and one a hold rating.
• A recent investment by Creative Planning marked the acquisition of 10,000 shares of Inventiva, reflecting ongoing interest from institutional investors.
• As of the latest report, IVA stock opened at $4.59, with a one-year low of $1.53 and a high of $4.79, indicating some fluctuation in its market performance.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $13.00.

Separately, Piper Sandler assumed coverage on Inventiva in a research note on Wednesday. They set an "overweight" rating and a $26.00 target price for the company.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors own 19.06% of the company's stock.

Inventiva Stock Down 2.5%

NASDAQ IVA traded down $0.16 during trading on Wednesday, hitting $6.19. 189,339 shares of the company's stock were exchanged, compared to its average volume of 47,818. Inventiva has a fifty-two week low of $1.53 and a fifty-two week high of $6.50. The stock's 50 day moving average price is $3.65 and its two-hundred day moving average price is $3.36.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.